JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Ligand Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

186.76 1.18

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

186.31

Max

187.87

Pagrindiniai rodikliai

By Trading Economics

Pajamos

47M

4.8M

Pardavimai

2.3M

48M

Pelno marža

10.177

Darbuotojai

68

EBITDA

50M

9.7M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

-2.56% downside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

1B

3.6B

Ankstesnė atidarymo kaina

185.58

Ankstesnė uždarymo kaina

186.76

Naujienos nuotaikos

By Acuity

46%

54%

134 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Ligand Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-24 18:41; UTC

Uždarbis

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

2025-10-24 18:31; UTC

Uždarbis

Correction to Procter & Gamble to Focus on Innovation

2025-10-24 16:25; UTC

Pagrindinės rinkos jėgos

Obook Shares Rise, Company Secures New Money Transmitter Licenses

2025-10-24 21:24; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-24 21:24; UTC

Rinkos pokalbiai

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

2025-10-24 21:07; UTC

Uždarbis

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

2025-10-24 20:58; UTC

Uždarbis

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

2025-10-24 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-10-24 20:40; UTC

Uždarbis

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

2025-10-24 20:24; UTC

Uždarbis

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

2025-10-24 20:23; UTC

Uždarbis

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

2025-10-24 20:13; UTC

Uždarbis

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

2025-10-24 20:07; UTC

Rinkos pokalbiai

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

2025-10-24 19:40; UTC

Rinkos pokalbiai

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

2025-10-24 19:35; UTC

Rinkos pokalbiai

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

2025-10-24 19:33; UTC

Uždarbis

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

2025-10-24 19:29; UTC

Rinkos pokalbiai

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

2025-10-24 18:52; UTC

Uždarbis

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

2025-10-24 18:41; UTC

Uždarbis

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

2025-10-24 18:03; UTC

Uždarbis

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

2025-10-24 18:02; UTC

Uždarbis

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

2025-10-24 18:00; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

2025-10-24 16:57; UTC

Uždarbis

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

2025-10-24 16:54; UTC

Rinkos pokalbiai

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

2025-10-24 16:44; UTC

Rinkos pokalbiai
Uždarbis

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

2025-10-24 16:39; UTC

Rinkos pokalbiai
Uždarbis

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

2025-10-24 16:33; UTC

Uždarbis

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

2025-10-24 16:23; UTC

Uždarbis

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

2025-10-24 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-10-24 16:07; UTC

Uždarbis

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Ligand Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

-2.56% į apačią

12 mėnesių prognozė

Vidutinis 182.2 USD  -2.56%

Aukščiausias 206 USD

Žemiausias 155 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ligand Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

6 ratings

6

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

102.5 / 109.24Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Very Strong Bearish Evidence

Ilgalaikis periodas

Weak Bullish Evidence

Rinkos nuotaikos

By Acuity

134 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.
help-icon Live chat